Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Gregory G. Schwartz(University of Colorado Denver), Andreas M. Zeiher(Goethe University Frankfurt), Deepak L. Bhatt(Mount Sinai Hospital), Rafael Díaz(Estudios Clínicos Latinoamérica), Pierluigi Tricoci(CSL (United States)), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Robert Pordy(Inserm), Shaun G. Goodman(University of Toronto), Vera Bittner(University of Alabama at Birmingham), Robert A. Harrington(Clinical Research Institute), Harvey D. White(University of Auckland), Michael Szarek(St. Michael's Hospital), Jay M. Edelberg(Inserm), Angèle Moryusef(Inserm), William J. Sasiela(Inserm), Corinne Hanotin, Kirby Quintero(Inserm), Matthew T. Roe(Inserm), Jean‐François Tamby(Medical University of South Carolina), Philippe Gabríel Steg(Mount Sinai Hospital), Guillaume Lecorps(Inserm), J. Wouter Jukema(Leiden University Medical Center)
Cited by 3,505
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k